Menu
Search
|

Menu

Close
X

Eleven Biotherapeutics Inc EBIO.OQ (NASDAQ Stock Exchange Global Market)

0.94 USD
-- (--)
As of Feb 21
chart
Previous Close 0.94
Open --
Volume --
3m Avg Volume 167,291
Today’s High --
Today’s Low --
52 Week High 2.53
52 Week Low 0.63
Shares Outstanding (mil) 31.83
Market Capitalization (mil) 29.93
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
30
FY15
1
EPS (USD)
FY17
-0.911
FY16
0.053
FY15
-1.754
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.64
Price to Sales (TTM)
vs sector
23.94
8.67
Price to Book (MRQ)
vs sector
1.36
5.21
Price to Cash Flow (TTM)
vs sector
--
26.03
Total Debt to Equity (MRQ)
vs sector
0.00
15.38
LT Debt to Equity (MRQ)
vs sector
0.00
12.01
Return on Investment (TTM)
vs sector
-36.85
13.57
Return on Equity (TTM)
vs sector
-88.92
15.19

EXECUTIVE LEADERSHIP

Daniel Lynch
Chairman of the Board, Since 2014
Salary: --
Bonus: --
Stephen Hurly
President, Chief Executive Officer, Director, Since 2016
Salary: --
Bonus: --
Richard Fitzgerald
Chief Financial Officer, Treasurer, Secretary, Since 2018
Salary: --
Bonus: --
Glen MacDonald
Chief Scientific Officer, Since 2016
Salary: --
Bonus: --
Gregory Adams
Chief Development Officer, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

245 1st St Ste 1800
CAMBRIDGE   MA   02142-1292

Phone: +1617.4448550

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company's product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company's therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).

SPONSORED STORIES